Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
March 2020
-
Press release
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,… -
Press release
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory… -
Ad hoc release
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at… -
Press release
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk… -
Press release
Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R… -
Featured News
Novartis coronavirus update (remote working, business travel restrictions)
-
Featured News
Novartis provides update on use and safety of Beovu® in patients with wet AMD
-
Story Discovery
The data42 program shows Novartis’ intent to go big on data and digital
Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.
-
Story Discovery
Meet Achim, leading the data42 program
The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.
-
Statement
Novartis coronavirus update (supply chain, response measures, EFPIA R&D call)
-
Story People and Culture
Novartis Social Business Careers: improving health in lower income countries
This is the story of how three Novartis colleagues took a career decision to improve health in lower income countries.
-
Featured News
International Women’s Day 2020
To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.